当前位置: X-MOL 学术Sci. Rep. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
In vitro nephrotoxicity and anticancer potency of newly synthesized cadmium complexes.
Scientific Reports ( IF 3.8 ) Pub Date : 2019-10-11 , DOI: 10.1038/s41598-019-51109-9
Selda Abyar 1, 2 , Ali Akbar Khandar 1 , Roya Salehi 3 , Seyed Abolfazl Hosseini-Yazdi 1 , Effat Alizadeh 3 , Mehrdad Mahkam 4 , Amer Jamalpoor 2 , Jonathan M White 5 , Motahhareh Shojaei 1 , O Aizpurua-Olaizola 6 , Rosalinde Masereeuw 2 , Manoe J Janssen 2
Affiliation  

Complexes based on heavy metals have great potential for the treatment of a wide variety of cancers but their use is often limited due to toxic side effects. Here we describe the synthesis of two new cadmium complexes using N(4)-phenyl-2-formylpyridine thiosemicarbazone (L1) and 5-aminotetrazole (L2) as organic ligands and the evaluation of their anti-cancer and nephrotoxic potential in vitro. The complexes were characterized by Single-crystal X-ray data diffraction, 1HNMR, FT-IR, LC/MS spectrometry and CHN elemental analysis. Next, cytotoxicity of these cadmium complexes was evaluated in several cancer cell lines, including MCF-7 (breast), Caco-2 (colorectal) and cisplatin-resistant A549 (lung) cancer cell lines, as well as in conditionally-immortalized renal proximal tubule epithelial cell lines for evaluating nephrotoxicity compared to cisplatin. We found that both compounds were toxic to the cancer cell lines in a cell-cycle dependent manner and induced caspase-mediated apoptosis and caspase-independent cell death. Nephrotoxicity of these compounds was compared to cisplatin, a known nephrotoxic drug, in vitro. Our results demonstrate that compound {2}, but not compound {1}, exerts increased cytotoxicity in MCF-7 and A549 cell lines, combined with reduced nephrotoxic potential compared to cisplatin. Together these data make compound {2} a likely candidate for further development in cancer treatment.

中文翻译:

新合成镉配合物的体外肾毒性和抗癌效力。

基于重金属的复合物在治疗多种癌症方面具有巨大潜力,但由于毒性副作用,它们的使用常常受到限制。在这里,我们描述了使用N(4)-苯基-2-甲酰基吡啶硫代半脲(L1)和5-氨基四唑(L2)作为有机配体的两个新镉配合物的合成,以及它们在体外的抗癌和肾毒性潜力的评估。通过单晶X射线数据衍射,1HNMR,FT-IR,LC / MS光谱和CHN元素分析来表征该配合物。接下来,评估了这些镉复合物在几种癌细胞系中的细胞毒性,包括MCF-7(乳腺癌),Caco-2(结肠直肠)和耐顺铂A549(肺癌)癌细胞系,以及在条件永生化的肾近端小管上皮细胞系中评估与顺铂相比的肾毒性。我们发现这两种化合物均以细胞周期依赖性方式对癌细胞系具有毒性,并诱导caspase介导的凋亡和caspase依赖性细胞死亡。在体外,将这些化合物的肾毒性与已知的肾毒性药物顺铂进行了比较。我们的结果表明,与顺铂相比,化合物{2},而不是化合物{1},在MCF-7和A549细胞系中发挥增强的细胞毒性作用,并具有降低的肾毒性潜力。这些数据加在一起使化合物{2}成为癌症治疗中进一步发展的可能候选者。我们发现这两种化合物均以细胞周期依赖性方式对癌细胞系具有毒性,并诱导caspase介导的凋亡和caspase依赖性细胞死亡。在体外,将这些化合物的肾毒性与已知的肾毒性药物顺铂进行了比较。我们的结果表明,与顺铂相比,化合物{2},而不是化合物{1},在MCF-7和A549细胞系中发挥增强的细胞毒性作用,并具有降低的肾毒性潜力。这些数据加在一起使化合物{2}成为癌症治疗中进一步发展的可能候选者。我们发现这两种化合物均以细胞周期依赖性方式对癌细胞系具有毒性,并诱导caspase介导的凋亡和caspase依赖性细胞死亡。在体外,将这些化合物的肾毒性与已知的肾毒性药物顺铂进行了比较。我们的结果表明,与顺铂相比,化合物{2},而不是化合物{1},在MCF-7和A549细胞系中发挥增强的细胞毒性作用,并具有降低的肾毒性潜力。这些数据加在一起使化合物{2}成为癌症治疗中进一步发展的可能候选者。与顺铂相比,具有降低的肾毒性。这些数据加在一起使化合物{2}成为癌症治疗中进一步发展的可能候选者。与顺铂相比,具有降低的肾毒性。这些数据加在一起使化合物{2}成为癌症治疗中进一步发展的可能候选者。
更新日期:2019-10-12
down
wechat
bug